Michael E. McEvoy the founder of Metabolic Healing gives a summary of studies on the connection between cholesterol, Parkinson’s Disease, and statins. Cholesterol plays an important role in PD, yet it is very controversial for different reasons. A 2018 cohort study found higher total cholesterol and LDL was associated with a decreased risk of PD over time for men, but not for women. The 2008 Honolulu-Asia Aging study found PD incidence increased with decreasing LDL-C levels in a dose-dependent manner for men aged 71-75. A 2006 Rotterdam-based study found higher total cholesterol associated with a significantly decreased risk of PD in women only. A 2017 study of 2,322 PD patients found high cholesterol associated with lower PD risk. These studies establish that higher cholesterol is associated with lower PD risk.
Studies that have found statins were protective have been criticized for having significant population bias. As yet no study which has shown statin protection against PD has accounted for patients with hyperlipidemia (these studies have excluded patients with hyperlipidemia). A 2017 study investigating the possibility of statins used in association with PD suggested that statin use may facilitate the onset of pre-clinical PD.
Related research presented in the video